tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2024-14-3s1-26-34tumors-1344Research ArticleСтатьиМезотелиома редких локализаций. Лучшее по материалам конференции iMig2023https://orcid.org/0000-0002-4548-1026БарболинаТ. Д.

Татьяна Дмитриевна Барболина 

115478 Москва, Каширское шоссе, 24

127473 Москва, Делегатская ул., 20 / 1

katan4ik@list.ruФГБУ «НМИЦ онкологии им. Н. Н. Блохина» Минздрава России; Научно-образовательный институт непрерывного профессионального образования им. Н. Д. Ющука ФГБОУ ВО «Российский университет медицины» Минздрава РоссииRussian Federation202418112024143s12634Copyright © Барболина Т.Д., 20242024Барболина Т.Д.Барболина Т.Д.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/1344

Редкость заболевания, трудности диагностики и стадирования мезотелиомы брюшины и влагалищной оболочки яичка оказывают влияние на формирование единого мнения в лечении этого заболевания. Пеметрексед остается наилучшим препаратом как для системной, так и для внутрибрюшинной химиотерапии. В данной статье коротко представлена наиболее интересная информация по лечению мезотелиомы редких локализаций, доложенная на конференции IMig2023 во Франции.

мезотелиома брюшиныстадирование мезотелиомыиндекс канцероматозагипертермическая внутрибрюшинная химиотерапия (HIPEC)мезотелиома оболочек яичкаReferencesHuang J., Chan S.C., Pang W.S., et al. Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study. J Thorac Oncol 2023;18(6):792-802. https://doi.org/10.1016/j.jtho.2023.01.095Huang J., Chan S.C., Pang W.S., et al. Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study. J Thorac Oncol 2023;18(6):792-802. https://doi.org/10.1016/j.jtho.2023.01.095Offin M., Yang S-R., Egger J., et al. Molecular Characterization of Peritoneal Mesotheliomas. J Thorac Oncol 2022;17(3):455-460. https://doi.org/10.1016/j.jtho.2021.09.012Offin M., Yang S-R., Egger J., et al. Molecular Characterization of Peritoneal Mesotheliomas. J Thorac Oncol 2022;17(3):455-460. https://doi.org/10.1016/j.jtho.2021.09.012Leblay N., Lepretre F., Le Stang N., et al. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas. J Thorac Oncol 2017;12:724-733. https://doi.org/10.1016/j.jtho.2016.12.019Leblay N., Lepretre F., Le Stang N., et al. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas. J Thorac Oncol 2017;12:724-733. https://doi.org/10.1016/j.jtho.2016.12.019Testa J.R., Cheung M., Pei J., et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2012;43(10):1022-1025. https://doi.org/10.1038/ng.912Testa J.R., Cheung M., Pei J., et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2012;43(10):1022-1025. https://doi.org/10.1038/ng.912Valenzuela C.D., Solsky I.B., Erali R.A., et al. Long-term survival in patients treated with cytoreduction and heated intraperitoneal chemotherapy for peritoneal mesothelioma at a single high-volume center. Ann Surg Oncol 2023;30(5):2666-2675. https://doi.org/10.1245/s10434-022-13061-3Valenzuela C.D., Solsky I.B., Erali R.A., et al. Long-term survival in patients treated with cytoreduction and heated intraperitoneal chemotherapy for peritoneal mesothelioma at a single high-volume center. Ann Surg Oncol 2023;30(5):2666-2675. https://doi.org/10.1245/s10434-022-13061-3Beal E.W., Srinivas S., Shen C., et al. Conditional survival following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: an analysis from the US HIPEC Collaborative. Ann Surg Oncol 2023;30(3):1840-1849. https://doi.org/10.1245/s10434-022-12753-0Beal E.W., Srinivas S., Shen C., et al. Conditional survival following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: an analysis from the US HIPEC Collaborative. Ann Surg Oncol 2023;30(3):1840-1849. https://doi.org/10.1245/s10434-022-12753-0Ettinger D.S., Wood D.E., Stevenson J., et al. NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Peritoneal. Version 1.2023. Accessed May 1, 2023. To view the most recent version, visit https://www.nccn.orgEttinger D.S., Wood D.E., Stevenson J., et al. NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Peritoneal. Version 1.2023. Accessed May 1, 2023. To view the most recent version, visit https://www.nccn.orgKusamura S., Kepenekian V., Villeneuve L., et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2021;47(1):36-59. https://doi.org/10.1016/j.ejso.2020.02.011Kusamura S., Kepenekian V., Villeneuve L., et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2021;47(1):36-59. https://doi.org/10.1016/j.ejso.2020.02.011Jacquet P., Sugarbaker P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: principle s of management. Boston, MA: Springer; 1996. pp. 359-374.Jacquet P., Sugarbaker P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: principle s of management. Boston, MA: Springer; 1996. pp. 359-374.Yan T.D., Deraco M., Elias D., et al. A novel tumor-node metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer 2011;117(9):1855-63. https://doi.org/10.1002/cncr.25640Yan T.D., Deraco M., Elias D., et al. A novel tumor-node metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer 2011;117(9):1855-63. https://doi.org/10.1002/cncr.25640Morris M.C., Cloyd J.M., Hays J., Patel S.H. The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies. J Gastrointest Surg 2021;25(1):303-318. https://doi.org/10.1007/s11605-020-04771-8Morris M.C., Cloyd J.M., Hays J., Patel S.H. The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies. J Gastrointest Surg 2021;25(1):303-318. https://doi.org/10.1007/s11605-020-04771-8Sugarbaker P.H., Chang D., Jelinek J.S. In 100 patients with malignant peritoneal mesothelioma, concerning CT features predicted outcome of treatment. Eur J Surg Oncol 2021;47(9):2212-2219. https://doi.org/10.1016/j-ejso.2021.04.012Sugarbaker P.H., Chang D., Jelinek J.S. In 100 patients with malignant peritoneal mesothelioma, concerning CT features predicted outcome of treatment. Eur J Surg Oncol 2021;47(9):2212-2219. https://doi.org/10.1016/j-ejso.2021.04.012Sugarbaker P.H., Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol 2017;43(7):1228-35. https://doi.org/10.1016/j.ejso.2017.01.009Sugarbaker P.H., Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol 2017;43(7):1228-35. https://doi.org/10.1016/j.ejso.2017.01.009Nazemi A., Nassiri N., Pearce S., Daneshmand S. Testicular Mesothelioma: An Analysis of Epidemiology, Patient Outcomes, and Prognostic Factors. Urology 2019;126:140-144. https://doi.org/10.1016/j.urology.2019.01.009Nazemi A., Nassiri N., Pearce S., Daneshmand S. Testicular Mesothelioma: An Analysis of Epidemiology, Patient Outcomes, and Prognostic Factors. Urology 2019;126:140-144. https://doi.org/10.1016/j.urology.2019.01.009

The authors declare that there are no conflicts of interest present.